Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
BREAST CANCER / BASIC RESEARCH
Evaluating the potential causal relationship between carnitine-related metabolites and breast cancer: a Mendelian randomization and transcriptomic analysis
1
Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
2
Department of Oncology, The Sixth Affiliated Hospital of Guangxi Medical University, The First People’s Hospital of Yulin, Yulin, Guangxi, China
These authors had equal contribution to this work
Submission date: 2025-10-16
Final revision date: 2025-12-18
Acceptance date: 2025-12-29
Online publication date: 2026-04-03
Publication date: 2026-04-12
Corresponding author
Rensheng Wang
Department of Radiation Oncology The First Affiliated Hospital of Guangxi Medical University No. 6, Shuangyong Road Qingxiu District Nanning, Guangxi 530000, China Phone: 13807806008
Department of Radiation Oncology The First Affiliated Hospital of Guangxi Medical University No. 6, Shuangyong Road Qingxiu District Nanning, Guangxi 530000, China Phone: 13807806008
Leifeng Liang
Department of Oncology The Sixth Affiliated Hospital of Guangxi Medical University The First People’s Hospital of Yulin No. 495, Jiaoyu Middle Road Yuzhou District, Yulin Guangxi, 537000, China Phone: 13657757927
Department of Oncology The Sixth Affiliated Hospital of Guangxi Medical University The First People’s Hospital of Yulin No. 495, Jiaoyu Middle Road Yuzhou District, Yulin Guangxi, 537000, China Phone: 13657757927
Arch Med Sci 2026;22(3):1688-1705
KEYWORDS
female malignant tumorsfatty acid metabolic intermediatesgenetic causal inferencetumor microenvironment regulation
TOPICS
ABSTRACT
Introduction:
Breast cancer (BC) is the most common malignancy among women worldwide. Although observational studies have linked carnitine-related metabolites (CRMs) to BC, causal inference has been limited by confounding and reverse causality. This study used Mendelian randomization (MR) analysis to investigate the potential causal link between CRMs and BC.
Material and methods:
MR analysis was conducted using the Cancer Genome Atlas-BC and CRM-related datasets to explore the potential causal relationship between CRMs and BC. Variants were screened based on criteria encompassing genome-wide significance (p < 5×10–8), independence (r² < 0.001, kb=10000), and sufficient strength (F-statistic > 10). Various MR techniques, including inverse-variance weighted, MR-Egger, simple mode, weighted mode, and weighted median approaches, were applied to assess these potential causal associations. Single-cell RNA sequencing (scRNA-seq) was employed to investigate the expression and biological functions of biomarkers linked to metabolites.
Results:
The MR analysis suggested that genetically predicted elevated levels of octanoylcarnitine and decanoylcarnitine were associated with increased risk of BC. Functional enrichment analysis identified 12 candidate genes associated with these metabolites, which are involved in fatty acid -oxidation (FAO) pathways. ScRNA-seq analysis revealed eight distinct cell subpopulations, with macrophages exhibiting the highest intercellular communication. Six biomarkers were identified as potential contributors to BC development: ACADM, FNIP2, RAPGEF2, RABGGTB, PPID, and ST6GALNAC3.
Conclusions:
This study provides evidence supporting potential causal associations between octanoylcarnitine and decanoylcarnitine and BC risk. Integrative single-cell transcriptomics revealed six CRM-associated biomarkers and their dynamic expression within tumor microenvironments. Additional experimental and clinical studies are needed to validate these observations and clarify their biological and translational relevance.
Breast cancer (BC) is the most common malignancy among women worldwide. Although observational studies have linked carnitine-related metabolites (CRMs) to BC, causal inference has been limited by confounding and reverse causality. This study used Mendelian randomization (MR) analysis to investigate the potential causal link between CRMs and BC.
Material and methods:
MR analysis was conducted using the Cancer Genome Atlas-BC and CRM-related datasets to explore the potential causal relationship between CRMs and BC. Variants were screened based on criteria encompassing genome-wide significance (p < 5×10–8), independence (r² < 0.001, kb=10000), and sufficient strength (F-statistic > 10). Various MR techniques, including inverse-variance weighted, MR-Egger, simple mode, weighted mode, and weighted median approaches, were applied to assess these potential causal associations. Single-cell RNA sequencing (scRNA-seq) was employed to investigate the expression and biological functions of biomarkers linked to metabolites.
Results:
The MR analysis suggested that genetically predicted elevated levels of octanoylcarnitine and decanoylcarnitine were associated with increased risk of BC. Functional enrichment analysis identified 12 candidate genes associated with these metabolites, which are involved in fatty acid -oxidation (FAO) pathways. ScRNA-seq analysis revealed eight distinct cell subpopulations, with macrophages exhibiting the highest intercellular communication. Six biomarkers were identified as potential contributors to BC development: ACADM, FNIP2, RAPGEF2, RABGGTB, PPID, and ST6GALNAC3.
Conclusions:
This study provides evidence supporting potential causal associations between octanoylcarnitine and decanoylcarnitine and BC risk. Integrative single-cell transcriptomics revealed six CRM-associated biomarkers and their dynamic expression within tumor microenvironments. Additional experimental and clinical studies are needed to validate these observations and clarify their biological and translational relevance.
REFERENCES (64)
1.
Giaquinto A, Sung H, Miller K, et al. Breast Cancer Statistics, 2022. CA Cancer J Clin 2022; 72: 524-41.
2.
Elbasheer MMA, Dodwell D, Gathani T. Understanding global variation in breast cancer mortality. Br J Radiol 2025; 98: 1369-72.
3.
Freihat O, Sipos D, Kovacs A. Global burden and projections of breast cancer incidence and mortality to 2050: a comprehensive analysis of GLOBOCAN data. Front Public Health 2025; 13: 1622954.
4.
Duan H, Zhang Y, Qiu H, Fu X, Liu C, Zang X, et al. Machine learning-based prediction model for distant metastasis of breast cancer. Comput Biol Med 2024; 169: 107943.
5.
Huang J, Lin Q. Correlation between multimodality imaging features and molecular subtypes in breast cancer: a comparative study between young (≤ 30 years) and middle-aged (45-55 years) women. Quant Imaging Med Surg 2025; 15: 7537-54.
6.
Engmann NJ, Golmakani MK, Miglioretti DL, Sprague BL, Kerlikowske K. Population-attributable risk proportion of clinical risk factors for breast cancer. JAMA Oncol 2017; 3: 1228-36.
7.
Hu T, Huang J, Fang K. Overall survival in patients with mucinous carcinoma of breast: a population-based study. Int J Gen Med 2021; 14: 9991-10001.
8.
Jaiswal A, Kaushik N, Choi EH, Kaushik NK. Functional impact of non-coding RNAs in high-grade breast carcinoma: Moving from resistance to clinical applications: a comprehensive review. Biochim Biophys Acta Rev Cancer 2023; 1878: 188915.
9.
Miller K, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin 2022; 72: 409-36.
10.
Yu J, Mu Q, Fung M, Xu X, Zhu L, Ho RJY. Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response. Pharmacol Ther 2022; 236: 108108.
11.
An J, Peng C, Tang H, Liu X, Peng F. New advances in the research of resistance to neoadjuvant chemotherapy in breast cancer. Int J Mol Sci 2021; 22: 9644.
12.
Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21: 297-308.
13.
Thakur C, Qiu Y, Pawar A, Chen F. Epigenetic regulation of breast cancer metastasis. Cancer Metastasis Rev 2024; 43: 597-619.
14.
Becker LM, O’Connell JT, Vo AP, Cain MP, Tampe D, Bizarro L, et al. Epigenetic reprogramming of cancer-associated fibroblasts deregulates glucose metabolism and facilitates progression of breast cancer. Cell Rep 2020; 31: 107701.
15.
Wang Y, Dang H, Wang Q, et al. Mitochondrial pyruvate dehydrogenase phosphatase metabolism disorder in malignant tumors. Oncol Res 2025; 33: 1861-74.
16.
Li S, Peng M, Tan S, et al. The roles and molecular mechanisms of non-coding RNA in cancer metabolic reprogramming. Cancer Cell Int 2024; 24: 37.
17.
Chakraborty S, Kumar AS, Banerjee S. Lipids: driving forces in the underlying biology of carcinogenesis. ACS Pharmacol Transl Sci 2025; 8: 1891-918.
18.
Castelli S, De Falco P, Ciccarone F, Desideri E, Ciriolo MR. Lipid catabolism and ROS in cancer: a bidirectional liaison. Cancers 2021; 13: 5484.
19.
Andolino C, Cotul EK, Xianyu Z, et al. Fatty acid synthase-derived lipid stores support breast cancer metastasis. Cancer Metab 2025; 13: 35.
20.
Longo N, Frigeni M, Pasquali M. Carnitine transport and fatty acid oxidation. Biochim Biophys Acta 2016; 1863: 2422-35.
21.
Zhang J, Wu G, Zhu H, et al. Circulating carnitine levels and breast cancer: a matched retrospective case-control study. Front Oncol 2022; 12: 891619.
22.
Smith GD, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003; 32: 1-22.
23.
Ference BA. Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps. Curr Opin Lipidol 2015; 26: 566-71.
24.
Wu SZ, Al-Eryani G, Roden DL, et al. A single-cell and spatially resolved atlas of human breast cancers. Nat Genet 2021; 53: 1334-47.
25.
Clarke C, Madden SF, Doolan P, et al. Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis 2013; 34: 2300-8.
26.
The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
27.
Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 2018; 7: e34408.
28.
Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015; 44: 512-25.
29.
Bowden J, Davey Smith G, Haycock P, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 2016; 40: 304-14.
30.
Burgess S, Scott R, Timpson N, Davey Smith G, Thompson S. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol 2015; 30: 543-52.
31.
Hartwig F, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol 2017; 46: 1985-98.
32.
Bou Sleiman M, Jha P, Houtkooper R, Williams RW, Wang X, Auwerx J. The gene-regulatory footprint of aging highlights conserved central regulators. Cell Rep 2020; 32: 108203.
33.
Rao S, Mondragón L, Pranjic B, et al. AIF-regulated oxidative phosphorylation supports lung cancer development. Cell Res 2019; 29: 579-91.
34.
Hao Y, Hao S, Andersen-Nissen E, et al. Integrated analysis of multimodal single-cell data. Cell 2021; 184: 3573-87.e29.
35.
Satija R, Farrell J, Gennert D, Schier A, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol 2015; 33: 495-502.
36.
Aran D, Looney A, Liu L, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol 2019; 20: 163-72.
37.
Jin S, Guerrero-Juarez C, Zhang L, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun 2021; 12: 1088.
38.
Xiaoning W, Guixin W, Qiaoqiao X, et al. Potential tumor-specific antigens and immune landscapes identification for mRNA vaccine in thyroid cancer. Front Oncol 2024; 14: 1480028.
39.
Shukla V, Rao M, Zhang H, et al. ASXL3 is a novel pluripotency factor in human respiratory epithelial cells and a potential therapeutic target in small cell lung cancer. Cancer Res 2017; 77: 6267-81.
40.
Yuanbin R, Katerina J K, Boris T, et al. The multiMiR R package and database: integration of microRNA-target interactions along with their disease and drug associations. Nucleic Acids Res 2014; 42: e133.
41.
Wilcoxon F. Individual comparisons of grouped data by ranking methods. J Econ Entomol 1946; 39: 269-70.
42.
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023-75.
43.
Howard FM, Olopade OI. Epidemiology of triple-negative breast cancer: a review. Cancer J 2021; 27: 8-16.
44.
Jin X, Zhou Y, Ma D, et al. Molecular classification of hormone receptor-positive HER2-negative breast cancer. Nat Genet 2023; 55: 1696-708.
45.
Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis 2016; 5: e189.
46.
Lou S, Balluff B, Cleven AHG, Bovée J, McDonnell LA. Prognostic metabolite biomarkers for soft tissue sarcomas discovered by mass spectrometry imaging. J Am Soc Mass Spectrom 2017; 28: 376-83.
47.
Park J, Shin Y, Kim TH, Kim DH, Lee A. Plasma metabolites as possible biomarkers for diagnosis of breast cancer. PLoS One 2019; 14: e0225129.
48.
Wang Z, Wang C, Gao X. Exploring metabolic pathways in gastrointestinal cancer: new evidence of causality. Discov Oncol 2025; 16: 1777.
49.
Huang Y, Lin W, Zheng X. Causal association between 637 human metabolites and ovarian cancer: a mendelian randomization study. BMC Genom 2024; 25: 97.
50.
Breeur M, Ferrari P, Dossus L, et al. Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutrition. BMC Med 2022; 20: 351.
51.
Gunchick V, Brown E, Liu J, et al. Morphomics, survival, and metabolites in patients with metastatic pancreatic cancer. JAMA Netw Open 2024; 7: e2440047.
52.
Ye J, Wu S, Quan Q, et al. Fibroblast growth factor receptor 4 promotes triple-negative breast cancer progression via regulating fatty acid metabolism through the AKT/RYR2 signaling. Cancer Med 2024; 13: e70439.
53.
Zeng F, Yao M, Wang Y, et al. Fatty acid -oxidation promotes breast cancer stemness and metastasis via the miRNA-328-3p-CPT1A pathway. Cancer Gene Ther 2022; 29: 383-95.
54.
Loo SY, Toh LP, Xie WH, et al. Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancer. Sci Adv 2021; 7: eabh2443.
55.
Potter S. Single-cell RNA sequencing for the study of development, physiology and disease. Nat Rev Nephrol 2018; 14: 479-92.
56.
Lee AH, Happerfield LC, Bobrow LG, Millis RR. Angiogenesis and inflammation in invasive carcinoma of the breast. J Clin Pathol 1997; 50: 669-73.
57.
Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254-65.
58.
Huang X, Cao J, Zu X. Tumor-associated macrophages: an important player in breast cancer progression. Thorac Cancer 2022; 13: 269-76.
59.
Zhang T, Yu J, Cheng S, et al. Research Progress on the anticancer molecular mechanism of targets regulating cell autophagy. Pharmacology 2023; 108: 224-37.
60.
Hu M, Fan JX, He ZY, Zeng J. The regulatory role of autophagy between TAMs and tumor cells. Cell Biochem Funct 2024; 42: e3984.
61.
Hao Y, Duan F, Dong X, et al. Gold nanoparticle inhibits the tumor-associated macrophage M2 polarization by inhibiting m(6)A methylation-dependent ATG5/autophagy in prostate cancer. Anal Cell Pathol 2025; 2025: 6648632.
62.
Zheqiong T, Yaru Z, Man Z, et al. Carnitine palmitoyl transferase 1A is a novel diagnostic and predictive biomarker for breast cancer. BMC Cancer 2021; 21: 409.
63.
Huang D, Li T, Li X, et al. HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression. Cell Rep 2014; 8: 1930-42.
64.
Seok S, Kim Y, Byun S, et al. Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid -oxidation. J Clin Invest 2018; 128: 3144-59.
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
